Lineage’s lead cell delivery clinical program is Renevia®, a medical device that was developed as a replacement for whole adipose tissue in cell assisted lipotransfer (CAL) procedures.
In 2018, the Company submitted a design dossier for European Union (EU) market clearance (CE Mark) for the use of Renevia® as a device to aid in transferring a patient’s own adipose tissue to treat certain forms of facial lipoatrophy, or fat loss. Lineage anticipates receiving feedback from the EU regulatory agency in 2019. If approved, the Company intends to identify an external partner for commercialization of Renevia in Europe (Read more about Lineage’s Cell/Drug Delivery Technology).
We also have investments in public companies AgeX, Inc. (approximately 5%) and OncoCyte Corporation (approximately 24%).
We are a publicly traded company listed on the NYSE MKT under the symbol LCTX.